Aberdeen Group plc Has $15.73 Million Stake in Zimmer Biomet Holdings, Inc. $ZBH

Aberdeen Group plc lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 9.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 172,438 shares of the medical equipment provider's stock after purchasing an additional 15,536 shares during the quarter. Aberdeen Group plc owned 0.09% of Zimmer Biomet worth $15,728,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of ZBH. Ameriprise Financial Inc. grew its holdings in Zimmer Biomet by 236.0% during the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock worth $517,039,000 after buying an additional 3,208,596 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Zimmer Biomet by 251.3% during the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock worth $235,571,000 after buying an additional 1,488,918 shares in the last quarter. Nuveen LLC bought a new stake in Zimmer Biomet during the first quarter worth $155,891,000. Alyeska Investment Group L.P. bought a new stake in Zimmer Biomet during the first quarter worth $101,294,000. Finally, Boston Trust Walden Corp bought a new stake in Zimmer Biomet during the first quarter worth $54,108,000. Institutional investors own 88.89% of the company's stock.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the company's stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares of the company's stock, valued at $711,656.95. This represents a 18.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.70% of the stock is owned by corporate insiders.

Zimmer Biomet Stock Up 3.4%

Shares of NYSE ZBH opened at $98.34 on Wednesday. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $114.72. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The business's fifty day moving average price is $101.49 and its 200-day moving average price is $98.04. The stock has a market capitalization of $19.48 billion, a PE ratio of 23.93, a P/E/G ratio of 2.19 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts' consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2.08 billion for the quarter, compared to analysts' expectations of $2.06 billion. During the same quarter in the prior year, the firm earned $2.01 EPS. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet's dividend payout ratio is currently 23.36%.

Analysts Set New Price Targets

ZBH has been the subject of several recent research reports. BTIG Research upped their price target on Zimmer Biomet from $118.00 to $122.00 and gave the stock a "buy" rating in a report on Monday. Royal Bank Of Canada set a $111.00 price objective on Zimmer Biomet in a research note on Friday. Rothschild & Co Redburn started coverage on Zimmer Biomet in a research note on Thursday, September 18th. They issued a "buy" rating and a $130.00 price objective for the company. Evercore ISI reduced their price objective on Zimmer Biomet from $106.00 to $104.00 and set an "in-line" rating for the company in a research note on Tuesday, October 7th. Finally, Raymond James Financial upped their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Zimmer Biomet presently has a consensus rating of "Hold" and a consensus target price of $111.94.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.